The statement below was issued on 12 March 2015:
In addition to today’s news of continued expansion into the Asian market, Admedus announced that it is on track for the strongest quarter of CardioCel® sales, building on the foundation of key, global centre use that has been established over the past year."
|Given that the revenue for the 2nd quarter was $2.5 million, then if the above statement was correct, then sales of other products have declined significantly as the receipts were approximately $400k under the 2nd quarter with revenue static. No surprise that the market reacted with a 3.8% decrease.
The company owes its shareholders more frequent updates on the revenues and the breakdown of the revenue figures.
- Forums
- ASX - By Stock
- AVR
- Quarterly
Quarterly, page-84
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$18.00 |
Change
0.090(0.50%) |
Mkt cap ! $344.2M |
Open | High | Low | Value | Volume |
$18.00 | $18.00 | $18.00 | $6.174K | 343 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 581 | $18.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.19 | 36 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 681 | 18.000 |
1 | 94 | 17.810 |
2 | 451 | 17.800 |
1 | 443 | 17.700 |
1 | 26 | 17.650 |
Price($) | Vol. | No. |
---|---|---|
18.190 | 36 | 1 |
18.220 | 27 | 1 |
18.230 | 36 | 1 |
18.240 | 500 | 1 |
18.300 | 150 | 1 |
Last trade - 10.10am 16/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online